Related references
Note: Only part of the references are listed.Empagliflozin in Patients with Chronic Kidney Disease
William G. Herrington et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Association of Type 2 Diabetes Mellitus with Cognitive Function in Adults: A Prospective Cohort Study
Xiao Chen et al.
JOURNAL OF ALZHEIMERS DISEASE (2023)
What should European nephrology do with the new CKD-EPI equation?
Ron T. Gansevoort et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
S. E. E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Glycemic Targets: Standards of Care in Diabetes-2023
Nuha A. ElSayed et al.
DIABETES CARE (2023)
Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023
Nuha A. ElSayed et al.
DIABETES CARE (2023)
Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023
Nuha A. ElSayed et al.
DIABETES CARE (2023)
Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events
Yang Yang et al.
CARDIOVASCULAR DIABETOLOGY (2022)
Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial
Carolyn S. P. Lam et al.
CIRCULATION (2022)
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2022
DIABETES CARE (2022)
Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials
Ajay Chaudhuri et al.
DIABETES OBESITY & METABOLISM (2022)
Factors associated with successful dietary changes in an energy-reduced Mediterranean diet intervention: a longitudinal analysis in the PREDIMED-Plus trial
Cesar Fernandez-Lazaro et al.
EUROPEAN JOURNAL OF NUTRITION (2022)
Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring
Michael Yapanis et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)
Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations
Jose L. Gorriz et al.
DIABETES THERAPY (2022)
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
Adriaan A. Voors et al.
NATURE MEDICINE (2022)
Effect of bariatric surgery on long-term cardiovascular outcomes: a systematic review and meta-analysis of population-based cohort studies
Borui Tang et al.
SURGERY FOR OBESITY AND RELATED DISEASES (2022)
Targeted Strategy in Lipid-Lowering Therapy
Ezgi Dayar et al.
BIOMEDICINES (2022)
Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives
Rosanna Maccari et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Tirzepatide and prevention of chronic kidney disease
Catalina Bosch et al.
CLINICAL KIDNEY JOURNAL (2022)
The Global Burden of Type 2 Diabetes Attributable to Tobacco: A Secondary Analysis From the Global Burden of Disease Study 2019
Jianjun Bai et al.
FRONTIERS IN ENDOCRINOLOGY (2022)
Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes
Elisabeth Ng et al.
Australian Journal of General Practice (2022)
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
S. D. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
A review of cardiovascular benefits of SGLT2 inhibitors
Yingxia Zhang et al.
MEDICINE (2022)
Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC/EASD: data from a large Mediterranean population
Ana M. Cebrian-Cuenca et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses fromDECLARE-TIMI58
Avivit Cahn et al.
DIABETES OBESITY & METABOLISM (2021)
Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes
Brendon L. Neuen et al.
DIABETES OBESITY & METABOLISM (2021)
Diabetes remission after bariatric surgery
Maryna Chumakova-Orin et al.
WORLD JOURNAL OF DIABETES (2021)
Efficacy and Cardiovascular Safety of Sulfonylureas
Cornelius James Fernandez et al.
CURRENT DRUG SAFETY (2021)
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
Juan P. Frias et al.
DIABETES CARE (2021)
SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review
Carlos Escobar et al.
DIABETIC MEDICINE (2021)
Cardiometabolic Center of Excellence: A Novel Care Delivery Model for Secondary Prevention of Cardiovascular Disease in Type 2 Diabetes
Merrill Thomas et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2021)
Routine assessment of cognitive function in older patients with hypertension seen by primary care physicians: why and how-a decision-making support from the working group on 'hypertension and the brain' of the European Society of Hypertension and from the European Geriatric Medicine Society
Angelo Scuteri et al.
JOURNAL OF HYPERTENSION (2021)
Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial
Geltrude Mingrone et al.
LANCET (2021)
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
What's in a Name? Redefining Type 2 Diabetes Remission
Sanjay Kalra et al.
DIABETES THERAPY (2021)
Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update
Husam M. Salah et al.
AMERICAN HEART JOURNAL (2021)
Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis
Dario Giugliano et al.
DIABETES OBESITY & METABOLISM (2021)
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial
Melanie Davies et al.
LANCET (2021)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Insulin Withdrawal in Diabetic Kidney Disease: What Are We Waiting for?
Carlos Morillas et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)
GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials
Apostolos Tsapas et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2021)
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)
Frank L. J. Visseren et al.
EUROPEAN HEART JOURNAL (2021)
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Bertram Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
Juan P. Frias et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti-hyperglycaemic drug matters?
Dario Giugliano et al.
DIABETES OBESITY & METABOLISM (2020)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss
Ahmad Al-Mrabeh et al.
CELL METABOLISM (2020)
Mechanisms and Characteristics of Sulfonylureas and Glinides
Wei Lv et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2020)
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETOLOGIA (2020)
Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
Athena Philis-Tsimikas et al.
DIABETOLOGIA (2020)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2020 EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2020)
Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the CanadianLMCdiabetes registry (SPAREstudy)
Ruth E. Brown et al.
DIABETES OBESITY & METABOLISM (2020)
Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis
Xing Wang et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
Juan J. Gorgojo-Martinez et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Renal protection with glucagon-like peptide-1 receptor agonists
Martina Vitale et al.
CURRENT OPINION IN PHARMACOLOGY (2020)
Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis
Xiaoyan Cai et al.
BMJ-British Medical Journal (2020)
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
Carolyn F. Deacon
NATURE REVIEWS ENDOCRINOLOGY (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art
Michael A. Nauck et al.
MOLECULAR METABOLISM (2020)
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2 Subgroup Analysis of the Randomized CREDENCE Trial
George Bakris et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Bloqueantes del receptor mineralcorticoide en la enfermedad renal crónica
Sara Erraez et al.
NEFROLOGIA (2020)
Risk of Coronary Heart Disease Among Smokeless Tobacco Users: Results of Systematic Review and Meta-Analysis of Global Data
Ruchika Gupta et al.
NICOTINE & TOBACCO RESEARCH (2019)
What is new in lipid-lowering therapies in diabetes?
Yee-Ming Cheung et al.
INTERNAL MEDICINE JOURNAL (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Tadej Battelino et al.
DIABETES CARE (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes
Maka S. Hedrington et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Long-term outcomes of macrovascular diseases and metabolic indicators of bariatric surgery for severe obesity type 2 diabetes patients with a meta-analysis
Guoli Yan et al.
PLOS ONE (2019)
The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States
Wayne Weng et al.
ENDOCRINOLOGY DIABETES & METABOLISM (2019)
Thiazolidinediones as antidiabetic agents: A critical review
M. J. Nanjan et al.
BIOORGANIC CHEMISTRY (2018)
Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
Bernard Zinman et al.
DIABETES CARE (2018)
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
Helena W. Rodbard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
Michael E. J. Lean et al.
LANCET (2018)
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Katherine R. Tuttle et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial
Serge A. Jabbour et al.
DIABETES CARE (2018)
2018 ESC/ESH Guidelines for the management of arterial hypertension
Bryan Williams et al.
EUROPEAN HEART JOURNAL (2018)
Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality
Yang Hu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
Thomas R. Pieber et al.
DIABETOLOGIA (2018)
Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
Bernard Zinman et al.
DIABETOLOGIA (2018)
The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes
Alexandra K. Lee et al.
DIABETES CARE (2018)
Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10-Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials
Costas Thomopoulos et al.
JOURNAL OF HYPERTENSION (2017)
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Long-Term Effects of Bariatric Surgery on Type 2 Diabetes Remission, Microvascular and Macrovascular Complications, and Mortality: a Systematic Review and Meta-Analysis
Binwu Sheng et al.
OBESITY SURGERY (2017)
Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials
Karine Suissa et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2017)
Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry®
Suzanne V. Arnold et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomised, multicentre trial
Olga Vaccaro et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
Rury R. Holman et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Simon J. Griffin et al.
DIABETOLOGIA (2017)
The impact of smoking on the development of diabetes and its complications
Mariola Sliwinska-Mosson et al.
DIABETES & VASCULAR DISEASE RESEARCH (2017)
Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies
Laurent Azoulay et al.
DIABETES CARE (2017)
Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial
Thomas Idorn et al.
DIABETES CARE (2016)
Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations
Francesco Rubino et al.
DIABETES CARE (2016)
Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial
Peter Gde et al.
DIABETOLOGIA (2016)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
W. Timothy Garvey et al.
ENDOCRINE PRACTICE (2016)
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
W. N. Kernan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial
Edward W. Gregg et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
N. M. Aldekhail et al.
OBESITY REVIEWS (2015)
Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
John M. Lachin et al.
DIABETES CARE (2014)
Severe Hypoglycemia-Induced Lethal Cardiac Arrhythmias Are Mediated by Sympathoadrenal Activation
Candace M. Reno et al.
DIABETES (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
被撤回的出版物: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet (Retracted article. See vol. 378, pg. 2441, 2018)
Ramon Estruch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis
Atsushi Goto et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Rosiglitazone, Myocardial Ischemic Risk, and Recent Regulatory Actions
Catherine A. Bourg et al.
ANNALS OF PHARMACOTHERAPY (2012)
Physical Activity and Mortality in Individuals With Diabetes Mellitus A Prospective Study and Meta-analysis
Diewertje Sluik et al.
ARCHIVES OF INTERNAL MEDICINE (2012)
Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study
F. Soriguer et al.
DIABETOLOGIA (2012)
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR (Part II)
L. Vanhees et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2012)
Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials
Bianca Hemmingsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Effects of Aerobic and Resistance Training on Hemoglobin A1c Levels in Patients With Type 2 Diabetes A Randomized Controlled Trial
Timothy S. Church et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study
Denise E. Bonds et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
Lisbeth V. Jacobsen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
Kausik K. Ray et al.
LANCET (2009)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effect of a multifactorial intervention on mortality in type 2 diabetes
Peter Gaede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents
Stephen N. Davis et al.
DIABETES CARE (2007)
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
DM Nathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial
JL Chiasson et al.
LANCET (2002)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
EJ Lewis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)